STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #4107 by analyst upside · 2026-08-12
BLFS
BioLife Solutions, Inc.
Healthcare · Market Cap $2B · P/E 34.8x
ANALYST PRICE TARGET
-10.2%
implied upside to consensus target
Current Price $34.82
Consensus Target $31.29
Bull Target $33.0
Bear Target $31.0
Analysts Covering 7
ANALYST CONSENSUS - HOLD
Strong Buy
0
Buy
1
Hold
6
Sell
0
52-Week Low $17.86
52-Week High $35.35
YTD Return +45.8%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) 34.8x
Forward P/E 105.5x
EPS (TTM) $1.00
PEG Ratio 15.09
Dividend Yield N/A
Revenue (TTM) $107M
Profit Margin 54.3%
52-WEEK RANGE
52-Week Low $17.86
52-Week High $35.35
Current Price $34.82
Bear Target $31.0
Bull Target $33.0
● Now $34.82 ● Target $31.29
TRADING DATA
Avg Volume 1.1M
YTD Return +45.8%
Analyst Count 7
Consensus Hold
Upside to Target -10.2%
Last Updated 2026-08-12

ANALYST SUMMARY

BioLife Solutions, Inc. (BLFS) is currently trading at $34.82 with a Wall Street consensus price target of $31.29, which is 10.2% below the current price over the next 12 months. 7 analysts currently cover BLFS, with a consensus rating of Hold - 14% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $33.0, while the most cautious has a target of $31.0.

BLFS operates in the Healthcare sector with a market capitalisation of $2B. The stock is up 45.8% year-to-date and is currently trading near the upper end of its 52-week range of $17.86 – $35.35.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for BLFS, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. reit
Buy → Buy 2025-12-29 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2025-11-24 31% win rate (48 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2025-08-08 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2025-05-13 31% win rate (48 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2025-03-06 31% win rate (48 calls)
Northland Capital Markets - Reiterated
Outperform → Outperform 2025-01-08 Building track record
Benchmark reit
Buy → Buy 2024-12-19 Building track record
Keybanc - Reiterated
Overweight → Overweight 2024-12-13 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
47
out of 100
Coverage depth
16/30
Consensus clarity
29/30
Vote unanimity
0/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →